HUP9902751A2 - Orális adagolású peptid gyógyászati készítmények - Google Patents
Orális adagolású peptid gyógyászati készítményekInfo
- Publication number
- HUP9902751A2 HUP9902751A2 HU9902751A HUP9902751A HUP9902751A2 HU P9902751 A2 HUP9902751 A2 HU P9902751A2 HU 9902751 A HU9902751 A HU 9902751A HU P9902751 A HUP9902751 A HU P9902751A HU P9902751 A2 HUP9902751 A2 HU P9902751A2
- Authority
- HU
- Hungary
- Prior art keywords
- surfactant
- acid
- composition
- active peptide
- agent
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 229940127557 pharmaceutical product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000003945 anionic surfactant Substances 0.000 abstract 2
- 239000003613 bile acid Substances 0.000 abstract 2
- 239000003093 cationic surfactant Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 230000001681 protective effect Effects 0.000 abstract 2
- 210000002784 stomach Anatomy 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 abstract 1
- 108010004977 Vasopressins Proteins 0.000 abstract 1
- 102000002852 Vasopressins Human genes 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 125000000129 anionic group Chemical group 0.000 abstract 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 abstract 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 abstract 1
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003904 phospholipids Chemical class 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 108010068072 salmon calcitonin Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 abstract 1
- 235000017557 sodium bicarbonate Nutrition 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- -1 sucrose ester Chemical class 0.000 abstract 1
- 239000006188 syrup Substances 0.000 abstract 1
- 235000020357 syrup Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Chemical class 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 229960003726 vasopressin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A találmány tárgya fiziőlógiásan aktív peptid hatóanyag őrálisadagőlására szőlgáló gyógyászati készítmény, amely készítményösszetevői: (A) terápiásan hatásős mennyiségű peptid hatóanyag; (B)legalább egy gyógyászati szempőntból elfőgadható pH-csökkentő szer;(C) legalább egy, a fenti hatóanyag biőlógiai hőzzáférhetőségételősegítő abszőrpciót főkőzó szer, és (D) a fenti gyógyászatikészítménynek a beteg győmrán való áthaladása sőrán a peptid hatóanyagés a győmőr prőteázők érintkezésének megakadályőzását biztősító sav-rezisztens védő-vivő anyag; ahől a pH-csökkentő szer a gyógyászatikészítményben őlyan mennyiségben van jelen, amely mennyiség 10 ml, 0,1mől/literes vizes nátriűm-hidrőgén-karbőnát-őldat pH-jának 5,5-re vagyaz alá való savanyításáhőz lenne elegendő. A találmány tárgya tővábbápeptid hatóanyag, legalább egy pH-csökkentő szer és legalább egyabszőrpciót főkőzó szer együttes alkalmazása, savrezisztens védő-vivőanyaggal főrmálva javítőtt biőlógiai hőzzáférhetőségű, őrálisadagőlású, bélben szabaddá váló gyógyászati készítményekelőállítására, amelyekben a pH-csökkentő szert és az egyébösszetevőket őlyan mennyiségben tartalmazzák, amelyek mellett a pH-csökkentő szer a bélben szabaddá válva őlyan savanyító hatást fejt ki,amely 10 ml 0,1 mől/literes vizes nátriűm-hidrőgén-karbőnát-őldat pH-jának 5,5-re vagy az alá való savanyításáhőz lenne elegendő. ŕ
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/616,250 US5912014A (en) | 1996-03-15 | 1996-03-15 | Oral salmon calcitonin pharmaceutical products |
PCT/US1997/004024 WO1997033531A1 (en) | 1996-03-15 | 1997-03-14 | Oral peptide pharmaceutical products |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP9902751A2 true HUP9902751A2 (hu) | 2000-01-28 |
HUP9902751A3 HUP9902751A3 (en) | 2001-04-28 |
HU226692B1 HU226692B1 (en) | 2009-06-29 |
Family
ID=24468632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9902751A HU226692B1 (en) | 1996-03-15 | 1997-03-14 | Oral peptide pharmaceutical products |
Country Status (18)
Country | Link |
---|---|
US (2) | US5912014A (hu) |
EP (1) | EP0929270B1 (hu) |
JP (1) | JP3549542B2 (hu) |
KR (1) | KR100498646B1 (hu) |
CN (1) | CN1197616C (hu) |
AT (1) | ATE284657T1 (hu) |
AU (1) | AU2211197A (hu) |
BR (1) | BR9708078A (hu) |
CA (1) | CA2249744C (hu) |
CZ (1) | CZ337198A3 (hu) |
DE (1) | DE69731957T2 (hu) |
ES (1) | ES2234011T3 (hu) |
HU (1) | HU226692B1 (hu) |
NO (1) | NO322443B1 (hu) |
NZ (1) | NZ331576A (hu) |
PT (1) | PT929270E (hu) |
RU (1) | RU2198677C2 (hu) |
WO (1) | WO1997033531A1 (hu) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
AU776995B2 (en) * | 1999-08-20 | 2004-09-30 | Virginia Tech Intellectual Properties, Inc. | Carnitine analogues as topical, microbicidal spermicides |
US6592869B2 (en) | 1999-08-24 | 2003-07-15 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
CA2382652A1 (en) | 1999-08-24 | 2001-03-01 | Teva Pharmaceutical Industries, Ltd. | A vaccine composition and method of using the same |
US6605591B1 (en) * | 1999-11-12 | 2003-08-12 | Genelabs Technologies, Inc. | Treatment of subnormal bone mineral density |
AU783952B2 (en) | 2000-02-04 | 2006-01-05 | Unigene Laboratories, Inc. | Nasal calcitonin formulations |
KR20080011353A (ko) | 2000-02-24 | 2008-02-01 | 몬산토 테크놀로지 엘엘씨 | 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들 |
EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
MXPA03000073A (es) * | 2000-06-26 | 2003-09-25 | Monsanto Technology Llc | Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina. |
US6664234B1 (en) * | 2000-06-30 | 2003-12-16 | Monsanto Technology Llc | Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US6664230B1 (en) | 2000-08-24 | 2003-12-16 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7166578B2 (en) | 2000-08-24 | 2007-01-23 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US7144862B2 (en) | 2000-08-24 | 2006-12-05 | The Regents Of The University Of California | Orally administered peptides to ameliorate atherosclerosis |
US7199102B2 (en) | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US6673574B2 (en) | 2000-11-30 | 2004-01-06 | Unigene Laboratories Inc. | Oral delivery of peptides using enzyme-cleavable membrane translocators |
US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
US7316819B2 (en) * | 2001-03-08 | 2008-01-08 | Unigene Laboratories, Inc. | Oral peptide pharmaceutical dosage form and method of production |
FR2822704B1 (fr) * | 2001-03-29 | 2005-02-18 | Chiesi Sa | Sels de cetoacides et d'acides amines gastroresistants et leur utilisation pour la preparation de medicaments |
US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
US20080194489A1 (en) * | 2001-12-21 | 2008-08-14 | Khan Nisar A | Treatment of iatrogenic disease |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US6930085B2 (en) | 2002-04-05 | 2005-08-16 | The Regents Of The University Of California | G-type peptides to ameliorate atherosclerosis |
US20040091544A1 (en) * | 2002-11-08 | 2004-05-13 | Ruff Michael D. | Coated dibasic calcium phosphate |
US8088734B2 (en) * | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
US20050019356A1 (en) * | 2003-07-25 | 2005-01-27 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using N-acyl amino acid compositions |
GB0308734D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Uptake of macromolecules |
GB0308732D0 (en) | 2003-04-15 | 2003-05-21 | Axcess Ltd | Absorption enhancers |
GB0315632D0 (en) * | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
BRPI0412265A (pt) | 2003-07-23 | 2006-09-05 | Novartis Ag | uso de calcitonina em osteoartrite |
US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
WO2005072803A1 (en) | 2004-01-16 | 2005-08-11 | Biodel, Inc. | Sublingual drug delivery device |
US20050215476A1 (en) * | 2004-01-21 | 2005-09-29 | Unigene Laboratories Inc. | Amidated parathyroid hormone fragments and uses thereof |
US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
CN101001641A (zh) * | 2004-04-29 | 2007-07-18 | 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 | 用于治疗代谢性骨病的包含骨形态发生蛋白的口服制剂 |
US20050282756A1 (en) * | 2004-06-18 | 2005-12-22 | Mehta Nozer M | Oral delivery of peptide pharmaceutical compositions |
CA2578202C (en) * | 2004-08-30 | 2013-12-17 | Toray Industries, Inc. | Fractionation apparatus |
RU2448977C2 (ru) * | 2004-09-16 | 2012-04-27 | Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье | Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью |
US7265090B2 (en) * | 2004-10-05 | 2007-09-04 | Gp Medical, Inc. | Nanoparticles for paracellular drug delivery |
AU2005314043A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
EP2269623A1 (en) * | 2005-04-29 | 2011-01-05 | The Regents of The University of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7964200B2 (en) | 2005-05-18 | 2011-06-21 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against Chlamydia infection |
SG163567A1 (en) * | 2005-07-05 | 2010-08-30 | Biotempt Bv | Treatment of tumors |
GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
EP1951207A2 (en) | 2005-11-17 | 2008-08-06 | Novartis AG | Pharmaceutical composition |
US8093207B2 (en) | 2005-12-09 | 2012-01-10 | Unigene Laboratories, Inc. | Fast-acting oral peptide pharmaceutical products |
CN100364610C (zh) * | 2005-12-12 | 2008-01-30 | 北京大学 | 提高蚓激酶口服吸收生物利用度的方法 |
EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
US20100034194A1 (en) * | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
US20100166734A1 (en) * | 2006-12-20 | 2010-07-01 | Edward Dolk | Oral delivery of polypeptides |
WO2008074868A1 (en) * | 2006-12-20 | 2008-06-26 | Ablynx N.V. | Oral delivery of polypeptides |
CA2677948C (en) * | 2007-02-12 | 2014-12-09 | Biotempt B.V. | Treatment of trauma-hemorrhage with short oligopeptides |
US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
US20100120694A1 (en) | 2008-06-04 | 2010-05-13 | Synergy Pharmaceuticals, Inc. | Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
DK2195331T3 (da) | 2007-08-28 | 2014-02-03 | Uab Research Foundation | Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
FR2925333B1 (fr) * | 2007-12-19 | 2012-04-13 | Farid Bennis | Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives |
US20090191645A1 (en) * | 2008-01-14 | 2009-07-30 | Washington University In St. Louis | Compounds and methods for modulating integrin activity |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010014830A2 (en) * | 2008-07-30 | 2010-02-04 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
CN101361881B (zh) * | 2008-09-09 | 2011-02-16 | 上海沈李科工贸有限公司 | 蛋白药物溶菌酶肠道吸收促进剂的制备方法 |
US9060927B2 (en) | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
EP2405934B1 (en) * | 2009-03-12 | 2014-03-26 | Nordic Bioscience A/S | Treatment of diabetes and metabolic syndrome |
US20100256060A1 (en) * | 2009-04-02 | 2010-10-07 | Unigene Laboratories Inc. | Peptide pharmaceuticals for nasal delivery |
US20140179607A9 (en) | 2009-11-09 | 2014-06-26 | Ironwood Pharmaceuticals, Inc | Treatments for Gastrointestinal Disorders |
WO2011071927A2 (en) | 2009-12-07 | 2011-06-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
WO2011084618A2 (en) | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
JP2013517833A (ja) | 2010-01-25 | 2013-05-20 | アルコン リサーチ, リミテッド | 擬調節可能な眼内メニスカスレンズ |
TR201711271T4 (tr) | 2010-02-17 | 2019-02-21 | Ironwood Pharmaceuticals Inc | Gastrointestinal Bozukluklar İçin Tedaviler |
CN101947315B (zh) * | 2010-09-03 | 2013-01-30 | 上海沈李科工贸有限公司 | 中药杏仁促进溶菌酶海藻酸钠微球肠道吸收的应用 |
MX354016B (es) | 2010-09-15 | 2018-02-07 | J Mrsny Randall | Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas. |
US11246915B2 (en) | 2010-09-15 | 2022-02-15 | Applied Molecular Transport Inc. | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo |
WO2012155114A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Peptides derived from uroguanylin and their use in gastrointestinal disorders |
US9650417B2 (en) | 2011-05-11 | 2017-05-16 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9527887B2 (en) | 2011-06-08 | 2016-12-27 | Ironwood Pharmaceutical, Inc. | Treatments for gastrointestinal disorders |
US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
CN104053449B (zh) | 2011-08-17 | 2016-12-07 | 硬木药品公司 | 胃肠疾患的治疗 |
SI3095484T1 (en) | 2011-11-02 | 2018-08-31 | Keybioscience Ag | Calcitonin mimetics for the treatment of diseases and disorders |
MX351092B (es) | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
WO2013067309A1 (en) * | 2011-11-04 | 2013-05-10 | Xion Pharmaceutical Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
HUE063336T2 (hu) | 2012-03-19 | 2024-01-28 | Cidara Therapeutics Inc | Adagolási rend echinokandin osztályba tartozó vegyületekhez |
JP5869419B2 (ja) * | 2012-05-07 | 2016-02-24 | 上野製薬株式会社 | 食品保存剤及び食品保存方法 |
CN104902922B (zh) | 2012-11-13 | 2017-12-12 | 阿道恰公司 | 包含经取代阴离子化合物的速效胰岛素制剂 |
JP2014114247A (ja) * | 2012-12-11 | 2014-06-26 | Capsugel Belgium Nv | 水中油型の乳剤およびその製造方法 |
EP2964193B1 (en) | 2013-03-05 | 2019-12-11 | Enteris BioPharma, Inc. | Pharmaceuticals for oral delivery |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP4398254A2 (en) | 2013-04-29 | 2024-07-10 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
EA201690732A1 (ru) | 2013-10-10 | 2016-12-30 | Синерджи Фармасьютикалз, Инк. | Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций |
RS57152B1 (sr) | 2013-11-14 | 2018-07-31 | Keybioscience Ag | Mimetici kalcitonina za lečenje bolesti i poremećaja |
AU2015226911B2 (en) | 2014-03-07 | 2018-03-01 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Non-narcotic CRMP2 peptides targeting sodium channels for chronic pain |
RU2723178C2 (ru) | 2014-05-07 | 2020-06-09 | ЭППЛАЙД МОЛЕКЬЮЛАР ТРАНСПОРТ ЭлЭлСи | Слитые молекулы, происходящие от Cholix-токсина, для пероральной доставки биологически активных нагрузок |
NZ727420A (en) | 2014-06-12 | 2018-06-29 | Ra Pharmaceuticals Inc | Modulation of complement activity |
EP3189069A4 (en) | 2014-07-31 | 2018-03-07 | UAB Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
AR102869A1 (es) | 2014-12-16 | 2017-03-29 | Lilly Co Eli | Composiciones de insulina de rápida acción |
GB201500263D0 (en) | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
WO2016115082A1 (en) * | 2015-01-12 | 2016-07-21 | Enteris Biopharma, Inc. | Solid oral dosage forms |
PT3250230T (pt) | 2015-01-28 | 2021-12-07 | Ra Pharmaceuticals Inc | Moduladores da atividade do complemento |
US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
LT3288578T (lt) | 2015-05-01 | 2023-04-25 | Ironwood Pharmaceuticals, Inc. | Kompozicijos, skirtos gaubtinės žarnos valymui ir virškinimo trakto sutrikimų gydymui |
AU2016271303C1 (en) * | 2015-06-01 | 2022-04-14 | Xeno Biosciences Inc. | Methods and compositions to modulate the gut microbiota and to manage weight |
JO3749B1 (ar) | 2015-08-27 | 2021-01-31 | Lilly Co Eli | تركيبات إنسولين سريعة المفعول |
EP3389692B1 (en) | 2015-12-16 | 2020-03-04 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
WO2017123634A1 (en) | 2016-01-11 | 2017-07-20 | Synergy Pharmaceuticals, Inc. | Formulations and methods for treating ulcerative colitis |
CN110267675B (zh) | 2016-08-05 | 2024-06-18 | 帕克治疗公司 | 室温稳定的口服降钙素制剂 |
US11123399B2 (en) | 2016-12-07 | 2021-09-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
GB201707955D0 (en) | 2017-05-18 | 2017-07-05 | Keybioscience Ag | Dual amylin and calcitonin receptor agonists for treating diseases and disorders |
AU2018275545B2 (en) | 2017-06-01 | 2021-02-04 | Eli Lilly And Company | Rapid-acting insulin compositions |
JP2018043990A (ja) * | 2017-10-11 | 2018-03-22 | カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップCapsugel Belgium NV | 水中油型の乳剤およびその製造方法 |
PT3762009T (pt) | 2018-03-08 | 2022-08-22 | Applied Molecular Transport Inc | Construções de administração derivadas de toxinas para administração oral |
SG11202009925PA (en) | 2018-03-08 | 2020-11-27 | Applied Molecular Transport Inc | Toxin-derived delivery constructs for oral delivery |
GB201813678D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
GB201813677D0 (en) | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
WO2020096695A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
BR112022002962A2 (pt) | 2019-08-16 | 2022-07-05 | Applied Molecular Transport Inc | Composições, formulações e produção e purificação de interleucina |
CN112494637B (zh) * | 2020-12-08 | 2023-05-23 | 中山大学附属第七医院(深圳) | 一种鲑鱼降钙素在制备用于治疗抑郁症药物中的应用 |
TW202330014A (zh) * | 2021-10-13 | 2023-08-01 | 日商中外製藥股份有限公司 | 含有胜肽化合物及界面活性劑之組成物 |
EP4226918A1 (en) | 2022-02-15 | 2023-08-16 | Filip Majewski | Pharmaceutical single dosage form for oral delivery of peptides |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56140924A (en) * | 1980-04-04 | 1981-11-04 | Teijin Ltd | Calcitonin pharmaceutical preparation |
US4604376A (en) * | 1982-04-21 | 1986-08-05 | Research Corporation | Enteric compounds and complexes |
US4708934A (en) * | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
US6319685B1 (en) * | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
US5288497A (en) * | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
IT1204400B (it) * | 1986-06-20 | 1989-03-01 | Sclavo Spa | Composizioni farmaceutiche contenente una calcitonina |
US5789234A (en) * | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
US5472710A (en) * | 1988-04-16 | 1995-12-05 | Schwarz Pharma Ag | Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture |
US5350741A (en) * | 1988-07-30 | 1994-09-27 | Kanji Takada | Enteric formulations of physiologically active peptides and proteins |
US4994439A (en) * | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
IT8920486A0 (it) * | 1989-05-12 | 1989-05-12 | Isf Spa | Composizioni farmaceutiche. |
GB9007052D0 (en) * | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
EP0489217A1 (en) * | 1990-12-05 | 1992-06-10 | Dr. A. Tosi Farmaceutici S.R.L. | Calcitonin compositions for intranasal administration |
AU653026B2 (en) * | 1991-06-07 | 1994-09-15 | Teikoku Seiyaku Kabushiki Kaisha | Physiologically active polypeptide-containing pharmaceutical composition |
US5206219A (en) * | 1991-11-25 | 1993-04-27 | Applied Analytical Industries, Inc. | Oral compositions of proteinaceous medicaments |
US5447729A (en) * | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
DE69528583T2 (de) * | 1994-04-22 | 2003-07-10 | Yamanouchi Pharma Co Ltd | Kolon-spezifisches arzneistofffreisetzungssystem |
-
1996
- 1996-03-15 US US08/616,250 patent/US5912014A/en not_active Expired - Lifetime
-
1997
- 1997-03-14 JP JP53285997A patent/JP3549542B2/ja not_active Expired - Lifetime
- 1997-03-14 CZ CZ983371A patent/CZ337198A3/cs unknown
- 1997-03-14 HU HU9902751A patent/HU226692B1/hu not_active IP Right Cessation
- 1997-03-14 CN CNB971930295A patent/CN1197616C/zh not_active Expired - Lifetime
- 1997-03-14 PT PT97915071T patent/PT929270E/pt unknown
- 1997-03-14 NZ NZ331576A patent/NZ331576A/xx not_active IP Right Cessation
- 1997-03-14 RU RU98118692/14A patent/RU2198677C2/ru not_active IP Right Cessation
- 1997-03-14 KR KR10-1998-0707287A patent/KR100498646B1/ko active IP Right Grant
- 1997-03-14 AT AT97915071T patent/ATE284657T1/de active
- 1997-03-14 WO PCT/US1997/004024 patent/WO1997033531A1/en not_active Application Discontinuation
- 1997-03-14 EP EP97915071A patent/EP0929270B1/en not_active Expired - Lifetime
- 1997-03-14 AU AU22111/97A patent/AU2211197A/en not_active Abandoned
- 1997-03-14 CA CA002249744A patent/CA2249744C/en not_active Expired - Lifetime
- 1997-03-14 BR BR9708078A patent/BR9708078A/pt not_active Application Discontinuation
- 1997-03-14 ES ES97915071T patent/ES2234011T3/es not_active Expired - Lifetime
- 1997-03-14 US US09/125,500 patent/US6086918A/en not_active Expired - Lifetime
- 1997-03-14 DE DE69731957T patent/DE69731957T2/de not_active Expired - Lifetime
-
1998
- 1998-09-14 NO NO19984243A patent/NO322443B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO984243D0 (no) | 1998-09-14 |
RU2198677C2 (ru) | 2003-02-20 |
US5912014A (en) | 1999-06-15 |
EP0929270B1 (en) | 2004-12-15 |
KR100498646B1 (ko) | 2005-12-16 |
NO984243L (no) | 1998-11-02 |
ATE284657T1 (de) | 2005-01-15 |
EP0929270A1 (en) | 1999-07-21 |
HU226692B1 (en) | 2009-06-29 |
JP3549542B2 (ja) | 2004-08-04 |
DE69731957T2 (de) | 2005-12-15 |
NZ331576A (en) | 2000-05-26 |
ES2234011T3 (es) | 2005-06-16 |
CZ337198A3 (cs) | 1999-04-14 |
JPH11508606A (ja) | 1999-07-27 |
WO1997033531A1 (en) | 1997-09-18 |
CN1197616C (zh) | 2005-04-20 |
KR19990087798A (ko) | 1999-12-27 |
DE69731957D1 (de) | 2005-01-20 |
US6086918A (en) | 2000-07-11 |
NO322443B1 (no) | 2006-10-09 |
HUP9902751A3 (en) | 2001-04-28 |
AU2211197A (en) | 1997-10-01 |
PT929270E (pt) | 2005-04-29 |
BR9708078A (pt) | 1999-07-27 |
CN1213282A (zh) | 1999-04-07 |
CA2249744C (en) | 2002-04-09 |
CA2249744A1 (en) | 1997-09-18 |
EP0929270A4 (en) | 2001-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0929270A4 (en) | ORAL PHARMACEUTICAL PRODUCTS WITH PEPTIDES | |
EP0742714B1 (en) | Liquid pharmaceutical compositions comprising thyroid hormones | |
CA2631841A1 (en) | Fast-acting oral peptide pharmaceutical products | |
AU617157B2 (en) | Intravaginal delivery of biologically active polypeptides | |
CA2430366A1 (en) | Improved oral delivery of peptides using enzyme-cleavable membrane translocators | |
WO1997007815A3 (en) | Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis | |
KR970705406A (ko) | 담즙산염과 활성 화합물의 생체 유효성을 증가시키기 위한 완충제를 함유하는 약학적 조성물(pharmaceutical compositions containing a bile salt and a buffer for increased bioavailability of an active compound) | |
Harris et al. | Bioadhesive polymers in peptide drug delivery | |
US5183802A (en) | Pharmaceutical compositions for intranasal administration of calcitonin | |
JP2021520391A (ja) | 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物 | |
EP0183527A2 (en) | Absorbable calcitonin medicament | |
EP1790334A3 (en) | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach | |
Bernkop-Schnürch et al. | Thiomers for oral delivery of hydrophilic macromolecular drugs | |
SI21026A (sl) | Stabilen, nasalno, oralno ali sublingvalno uporabljiv farmacevtski pripravek | |
ZA894828B (en) | Process for the preparation of anti-inflammatory pharmaceutical agents with an ibuprofen base,with elimination,in solution,of the bitter taste,burning of the throat and intestinal toxicity | |
KR900016253A (ko) | 아미드화 타우린 또는 글리신의 산부가염, 그의 제조방법과 용도 | |
EP0719148A1 (en) | Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt | |
US20070173447A1 (en) | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent | |
JP2012522787A (ja) | 経鼻送達のためのペプチド医薬組成物 | |
US5514365A (en) | Pharmaceutical compositions comprising calcitonin for intranasal administration | |
CA2362772A1 (en) | Pharmaceutical formulation for intraveous or intramuscular octreotide administration | |
WO1993006854A1 (en) | Pharmaceutical compositions comprising a calcitonin, a glycyrrhizinate as absorption enhancer and benzyl | |
EP0489217A1 (en) | Calcitonin compositions for intranasal administration | |
WO1998013001A1 (en) | Intranasal formulations for promoting sleep and method of using the same | |
CA1329764C (en) | Pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of definitive patent protection due to non-payment of fees |